IMPROVE Risk Score for Venous Thromboembolism (VTE)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very Low Risk0–0
- Low Risk1–1
- Moderate Risk2–2
- Moderate-High Risk3–3
The IMPROVE Risk Score for Venous Thromboembolism (VTE) calculates predicting 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. Key inputs include previous vte. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.
Clinical Indication
The IMPROVE Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Score = Previous VTE (3) + Known thrombophilia (2) + Current lower-limb paralysis (2) + Current cancer (2) + Immobilized ≥7 days (1) + ICU/CCU stay (1) + Age >60 years (1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| previous_vte | string | Yes | History of previous venous thromboembolism (deep vein thrombosis or pulmonary embolism). Previous VTE is the strongest risk factor, carrying the highest point value due to increased likelihood of recurrence |
| known_thrombophilia | string | Yes | Known thrombophilia or hereditary thrombotic disorder (Factor V Leiden, prothrombin gene mutation, antithrombin deficiency, protein C or S deficiency, antiphospholipid syndrome). Thrombophilic disorders increase VTE risk through various mechanisms affecting coagulation |
| current_lower_limb_paralysis | string | Yes | Current lower-limb paralysis or paresis affecting mobility. Paralysis increases VTE risk through venous stasis and reduced muscle pump function in affected limbs |
| current_cancer | string | Yes | Current active cancer diagnosis. Cancer increases VTE risk through multiple mechanisms including tumor-related procoagulant factors, chemotherapy effects, and reduced mobility |
| immobilized_7_days | string | Yes | Immobilized ≥7 days immediately prior to and during hospital admission. Prolonged immobilization increases VTE risk through venous stasis and activation of coagulation pathways |
| icu_ccu_stay | string | Yes | Current stay in intensive care unit (ICU) or coronary care unit (CCU). Critical care setting indicates severe illness with increased VTE risk from immobility, procedures, and systemic inflammation |
| age_over_60 | string | Yes | Age greater than 60 years. Advanced age increases VTE risk through age-related changes in coagulation factors, decreased mobility, and increased comorbidities |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Very Low Risk | Score 0 points |
| 1–1 | Low Risk | Score 1 point |
| 2–2 | Moderate Risk | Score 2 points |
| 3–3 | Moderate-High Risk | Score 3 points |
| 4–4 | High Risk | Score 4 points |
| 5–12 | Very High Risk | Score 5-12 points |
Evidence-Based References (EBM)
- Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944.DOI: 10.1378/chest.10-1944
- Hostler DC, Marx ES, Moores LK, et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk model. Chest. 2016 Apr;149(4):1002-1009. doi: 10.1378/chest.15-2082.DOI: 10.1378/chest.15-2082
- Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014 Nov 4;3(6):e001152. doi: 10.1161/JAHA.114.001152.DOI: 10.1161/JAHA.114.001152